Group 1 - The company, Kangtai Medical (300869), has recently obtained a medical device registration certificate from the Hebei Provincial Drug Administration for a disposable anesthesia laryngoscope [1] - The product is designed to assist in exposing the epiglottis to guide medical personnel in accurately performing airway intubation for anesthesia or emergency use [1] - The registered product models include G2, G3, G4, C2, C3, and C4, with the registration certificate number being冀械注准20252080126 [1] Group 2 - The approval date for the medical device is May 6, 2025, and it will be effective from the same date, remaining valid until May 5, 2030 [1] - The product can also be utilized for oral examinations and treatments [1]

证券代码：300869 证券简称：康泰医学 公告编号：2025-036 债券代码：123151 债券简称：康医转债 康泰医学系统（秦皇岛）股份有限公司 关于获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 康泰医学系统（秦皇岛）股份有限公司（以下简称"公司"）于近日取得了由 河北省药品监督管理局颁发的《中华人民共和国医疗器械注册证》，具体情况如下： 一、医疗器械注册证内容 注册人名称：康泰医学系统（秦皇岛）股份有限公司 产品名称：一次性使用麻醉窥视片 型号、规格：G2、G3、G4、C2、C3、C4 批准日期：2025 年 05 月 06 日 生效日期：2025 年 05 月 06 日 有效期至：2030 年 05 月 05 日 二、对公司的影响及风险提示 以上产品医疗器械注册证的取得，有利于丰富公司产品线，进一步提高公司的 核心竞争力，对公司发展具有正面影响。上述产品后期实际销售情况取决于未来市 场的推广效果及市场的实际需求，公司目前尚无法准确预测上述产品对公司未来营 业收入的影响，敬请广大投资者注意投资风险。 三、备查文件 《中华人民 ...

5月6日，康泰医学今日收盘13.92元，上涨2.35%，最新市净率3.03，创20天以来新低，总市值55.93亿 元。 股东方面，截至2025年3月31日，康泰医学股东户数31459户，较上次减少1578户，户均持股市值35.28 万元，户均持股数量2.76万股。 康泰医学系统(秦皇岛)股份有限公司的主营业务是医疗诊断、监护设备的研发、生产和销售。产品涵盖 血氧类、心电类、超声类、监护类、血压类等多个大类,建立了完善的研发、生产和销售体系。2023年4 月，公司Remoltar远程专业彩色多普勒超声诊断系统荣获德国IF设计奖和意大利A设计奖。2023年10 月，公司的儿童红外体温计产品斩获2023年广交会设计创新奖银奖，呼吸训练器、动态心电监护仪两款 产品斩获铜奖。 最新一期业绩显示，2025年一季报，公司实现营业收入1.12亿元，同比12.77%；净利润1643.58万元， 同比277.67%，销售毛利率58.15%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)9康泰医学-84.98-71.803.0355.93亿行业平均 48.9047.004.53103.78亿行业中值36.4137.242 ...

Group 1 - The core viewpoint of the reports indicates that Kangtai Medical achieved a revenue of 480 million yuan in 2024, with significant contributions from home-use products (184 million yuan) and hospital products (252 million yuan) [1] - In Q1 2025, Kangtai Medical reported a revenue of 112 million yuan, representing a year-on-year growth of 12.77%, and a net profit attributable to shareholders of 16 million yuan, up 277.67% year-on-year [1] - The company maintained a research and development investment exceeding 100 million yuan in 2024, despite overall performance pressures, and is advancing fundraising projects to deepen its industry chain layout [1] Group 2 - Kangtai Medical emphasizes technological innovation as its core competitiveness, with a research and development strategy focused on "innovation, efficiency, quality, cost reduction, and enhancement" [2] - The company invested 105 million yuan in R&D in 2024, resulting in 57 new domestic patents, including 11 invention patents and 46 utility and design patents, along with 15 software copyrights [2] - To address global business expansion and product diversification challenges, Kangtai Medical is implementing lean production models and optimizing production processes, including the introduction of SMT technology and automation in assembly [2] Group 3 - As of the end of the reporting period, Kangtai Medical had invested 92.53 million yuan from convertible bond fundraising, with the construction of the "Kangtai Industrial Park" project completed and entering the decoration phase [3] - The "Kangtai Medical Device Industrial Park" project in Beidaihe is set to commence construction in July 2024, with the main structure already topped out, providing critical support for future capacity ramp-up and large-scale production of new products [3] - Looking ahead to 2025, Kangtai Medical plans to continue its steady and innovative operational strategy, focusing on core business, maintaining R&D investment, enhancing product and service quality, and optimizing resource allocation to maximize shareholder and company benefits [3]

Core Viewpoint - The company, Kangtai Medical, operates in the medical device industry, focusing on the research, production, and sales of medical diagnostic and monitoring equipment, with a strong emphasis on enhancing operational efficiency and market potential despite weak downstream demand [4]. Company Overview - Kangtai Medical is a high-tech enterprise specializing in medical diagnostic and monitoring equipment, with a product range that includes blood oxygen, electrocardiogram, ultrasound, monitoring, blood pressure, and analytical testing devices, as well as digital health services [4]. - The company has established three main product systems: hospital-use, home-use, and other categories, serving various healthcare settings including hospitals, clinics, community health service centers, and individual households [4]. Financial Performance - The company's main business revenue accounted for 99.22% of total revenue during the reporting period, indicating a strong focus on core operations [4]. - The company received a standard unqualified audit opinion from Deloitte Huayong Accounting Firm, with no changes in the auditing firm during the reporting period [2][3]. Profit Distribution - The board of directors approved a profit distribution plan, proposing a cash dividend of 2.5 yuan (including tax) for every 10 shares, with no bonus shares issued [3]. Shareholder Information - The report includes details on the number of ordinary shareholders and the top 10 shareholders, with no changes in the major shareholders compared to the previous period [4]. Bond Information - The company maintains a long-term credit rating of A+ from United Ratings, with a stable outlook for its bonds [7].

Group 1 - The core business of Kangtai Medical is the research, production, and sales of medical diagnostic and monitoring equipment, covering various categories such as blood oxygen, electrocardiogram, ultrasound, monitoring, and blood pressure [1] - As of the first quarter of 2025, Kangtai Medical reported a revenue of 112 million yuan, representing a year-on-year increase of 12.77%, and a net profit of 16.44 million yuan, with a significant year-on-year increase of 277.67% [1] - The company achieved a gross profit margin of 58.15% in its latest earnings report [1] Group 2 - Kangtai Medical's stock closed at 12.41 yuan, down 1.90%, with a latest price-to-book ratio of 2.70 and a total market capitalization of 4.986 billion yuan [1] - The company has three institutional holders, including two funds and one other entity, with a total holding of 3.3463 million shares valued at 4.6 million yuan [1] - In April 2023, Kangtai Medical's Remoltar remote professional color Doppler ultrasound diagnostic system won the German IF Design Award and the Italian A Design Award [1]

证券代码：300869 证券简称：康泰医学 公告编号：2025-033 债券代码：123151 债券简称：康医转债 康泰医学系统（秦皇岛）股份有限公司 关于变更募集资金投资项目实施方式及项目办公楼 根据《康泰医学系统（秦皇岛）股份有限公司首次公开发行股票并在创业板 上市招股说明书》，公司首次公开发行股票募集所得资金扣除发行费用后投资项 目具体情况如下： 使用用途的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 康泰医学系统（秦皇岛）股份有限公司（以下简称"公司"或"康泰医学"） 于 2025 年 4 月 25 日召开第四届董事会第十八次会议和第四届监事会第十二次会 议，审议通过了《关于变更募集资金投资项目实施方式及项目办公楼使用用途的 议案》,公司拟将首次公开发行 A 股股票募集资金投资项目"智能医疗设备产业 研究院项目"办公楼由自用调整为对外出租，另行租赁适配该项目当前业务规模 的办公场地用于项目运营。 截至本公告披露之日，"智能医疗设备产业研究院项目"已结项，本次变更 不涉及募集资金的实际金额调整，该事项尚需提交公司 2024 年年度股东大会审 议。 ...

关于公司组织机构调整的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300869 证券简称：康泰医学 公告编号：2025-031 债券代码：123151 债券简称：康医转债 康泰医学系统（秦皇岛）股份有限公司 2025 年 4 月 29 日 附件： 康泰医学系统（秦皇岛）股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开了第四届董事会第十八次会议，审议通过了《关于公司组织机构调 整的议案》。为进一步满足公司业务发展和产业战略布局的需要，更好地完善公 司治理结构、提高管理效率、优化资源配置，并结合公司实际发展规划和经营管 理的需要，董事会决定对公司组织机构进行调整，调整后的组织机构详见附件。 本次组织机构调整是对公司内部管理机构的调整，不会对公司经营活动产生重大 影响。 特此公告。 康泰医学系统（秦皇岛）股份有限公司董事会 ...

康泰医学系统（秦皇岛）股份有限公司 董事会审计委员会对会计师事务所 2024 年度履职情况评估 及履行监督职责情况的报告 （6）德勤华永 2024 年末合伙人人数为 204 人，从业人员共 5,616 人，注册 会计师共 1,169 人，其中签署过证券服务业务审计报告的注册会计师超过 270 人。 （7）德勤华永 2023 年度经审计的业务收入总额为人民币 41 亿元，其中审 计业务收入为人民币 32 亿元，证券业务收入为人民币 6 亿元。 （8）德勤华永为 58 家上市公司提供 2023 年年报审计服务，审计收费总额 为人民币 2.60 亿元。德勤华永所提供服务的上市公司中主要行业为制造业，金 融业，房地产业，交通运输、仓储和邮政业，信息传输、软件和信息技术服务业。 2、投资者保护能力 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理 准则》《国有企业、上市公司选聘会计师事务所管理办法》《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》和《公司章程》等规 定和要求，康泰医学系统（秦皇岛）股份有限公司（以下简称"公司"）董事会 审计委员会本着勤勉尽责的原则，恪尽职守 ...

2024 年，康泰医学系统（秦皇岛）股份有限公司（以下简称"公司"）董 事会依照《公司法》《证券法》等法律法规、规范性文件以及《公司章程》《董 事会议事规则》等规定，本着对全体股东负责的精神，认真执行股东大会各项决 议，积极开展董事会各项工作，有效保障了公司的稳定发展和全体股东的合法权 益，现就公司董事会 2024 年度工作情况报告如下： 一、公司总体经营情况 2024 年，公司实现营业收入 47,980.52 万元，同比下降 35.76%，实现归属 于上市公司股东的净利润为-7,790.26 万元，同比下降 147.00%。公司业绩下滑 的主要原因为：主营业务收入下降、计提大额存货跌价准备以及研发费用发生额 依然较高。报告期内，受下游市场需求减弱以及激烈的市场竞争影响，公司主要 产品的销量及销售价格同比下降，主营业务收入随之下降；基于过去几年特殊的 市场环境，公司血氧类产品原材料及半成品存货余额偏高，受报告期内市场需求 降低的影响，公司相关存货周转放缓，血氧类产品原材料及半成品消耗速度低于 预期，加之其他常规类原材料及半成品使用效率不足，存货可变现净值降低，因 此，公司本年度计提存货跌价准备 10,944. ...